Funds raised in Imagion’s recent Rights Issue will be used to fund the first-in-human trials for the Company’s MagSense technology. Listen to CEO Bob Proulx further discuss Imagion’s progress in this recent interview with Boardroom Media.
Imagion Initiates Collaboration with Wayne State University to Develop Advanced Molecular Imaging Capabilities to Enable AI Cancer Diagnostics
August 13, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging